Evaluation Of Treatment Decisions Research Articles

Scaling hypertension treatment in 24 low-income and middle-income countries: economic evaluation of treatment decisions at three blood pressure cut-points

ObjectiveEstimate the incremental costs and benefits of scaling up hypertension care in adults in 24 select countries, using three different systolic blood pressure (SBP) treatment cut-off points—≥140, ≥150 and ≥160...

Machine learning-based prediction of dual primary breast cancer

IntroductionPredicting dual primary tumors in patients diagnosed with first-episode breast cancer (BC) is crucial. This can assist physicians’ evaluation of treatment decisions. We applied eight machine learning algorithms to the BC data from the Surveillance, Epidemiology, and End Results program (SEER) database and evaluated the best model for predicting dual primary BC to help physicians assess patient prognoses.Material and methodsMachine learning models were established based on the retrospective study of 253,991 patients diagnosed with first-episode BC in the SEER database from 2010 to 2015. External validation was conducted on 6012 cases obtained through undersampling from the SEER database from 2004 to 2009. The decision tree (DT) and random forest (RF) models were employed using ten-fold cross-validation and grid search.ResultsSurgical information, lymph-node status, distant metastasis, tumor size, survival time, and histological type had significant influence as inputs. Compared with those of the other seven models (multinomial naïve bayes, logistic regression, k-nearest neighbor, one-dimensional convolutional neural network, recurrent neural network, long short-term memory, and DT), the accuracy of the RF model increased from 63.25 to 97.19%, whereas its precision, recall, F1 score, and area under the curve (AUC) increased from 62.92 to 95.01%, 64.36 to 99.48%, 63.63 to 97.19%, and 63.25 to 97.10%, respectively. RF was the only model where the AUC increased (0.24%) under external verification, which shows its excellent portability and generalization in the validation cohort.ConclusionsThe RF model can be used to predict dual primary BC and assist physicians with the diagnosis and treatment of first-episode BC patients.

High exosomal PD-L1 expression in relation to lymph node progression in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (abi) or enzalutamide (enza).

e17038 Background: Programmed death-ligand 1 (PD-L1) has been recently found in tumor-derived exosomes and associated with progressive disease (PD) ( Poggio, Cell 2019). In localized prostate cancer, PD-L1 tumor expression has been shown to be a biomarker for node-positive patients (pts) ( Petitprez, Eur Urol Focus 2019) but its role in mCRPC is largely unexplored. We aimed to determine the potential of PD-L1 exosomal expression to predict lymph nodal PD in mCRPC receiving abi or enza. Methods: In a biomarker prospective study (REC 2192/2013), exosomes were isolated from plasma samples collected before first-line therapy with abi/enza between December 2014 and October 2018. RNA was extracted for analysis of PD-L1 by digital droplet PCR ( Del Re, Prostate Cancer Prostatic Dis 2021). Results: In our cohort of 55 node-positive mCRPC pts (median age: 76 years, range 47-89), the amount of exosomal PD-L1 expression (pts dichotomized in “high” and “low” as below or above median PD-L1/ACTB ratio = 0.0052) was associated with radiographic response after the first 3 months abi/enza therapy [high PD-L1 vs low PD-L1: 8 (25.8%) vs 0 (0%) PD, 23 (74.2%) vs 18 (75%) stable disease, and 0 vs 6 (25%) partial/complete response] (p = 0.0009). We observed an overall median progression-free survival (PFS) of 14.3 months [95% confidence interval (CI) 8.6-not reached] shorter in high PD-L1 compared to low PD-L1 10.6 (6.5-23.4) vs not reached [hazard ratio (HR) 3.1 (95% CI 1.1-8.5), p = 0.023]. In multivariable analysis including exosomal PD-L1 and androgen receptor (AR) variant 7, AR copy number gain detected in plasma, neutrophil lymphocyte ratio (NLR), lactate dehydrogenase, exosomal PD-L1; AR-V7 and AR gain were independent predictors of nodal PFS (HR 5.8, 95% CI 1.4-24.2, p = 0.01, HR 3.2, 95% CI 1.1-9.2, p = 0.03 and HR 12.9, 95% CI 2.3-73.2, p = 0.004), whereas AR-V7, AR gain, NLR > 3 were independent predictors of OS (HR 4.9, 95% CI 1.8-13.1, p = 0.001, HR 4.4, 95% CI 1.1-17, p = 0.02, and HR 3.2 95% CI 1.1-9.4, p = 0.03, respectively). Moreover, a trend of a worse OS was reported in high PD-L1 compared to low PD-L1 pts (HR 2.6, 95% CI 0.9-7.5, p = 0.07). Conclusions: In mCRPC pts treated with ARSI, exosomal PD-L1 expression may be considered as a predictive biomarker of lymph nodal response, playing a potential role in individualized disease monitoring and treatment combining between ARSI and immunotherapy. Larger evaluation of treatment decisions based on exosomal PD-L1 expression is now required.

"Will It Affect Our Chances of Having Children?" and Feeling "Like a Ticking Bomb" -The Fertility Concerns and Fears of Cancer Progression and Recurrence in Cancer Treatment Decision-Making Among Young Women Diagnosed With Gynaecological or Breast Cancer.

Objective: Cancer treatment decision making process is particularly fraught with challenges for young women because the treatment can affect their reproductive potential. Among many factors affecting the process, fears of cancer progression and recurrence can also be important psychological factors. Our aim is to apply Common-Sense Model and shared decision-making model to explore experiences of treatment decision-making women of reproductive age who were diagnosed with gynaecological or breast cancer and the influence of fertility issues and fears of cancer progression and recurrence.Method: We conducted telephone interviews with 24 women who were diagnosed with gynaecological or breast cancer aged 18–45, who finished active treatment within 5 years prior to study enrolment and had no known evidence of cancer recurrence at the time of participation. They were recruited from three NHS oncology clinics in Scotland and online outlets of cancer charities and support organisations. We analysed the data using Braun and Clarke's thematic analysis method as it allows for both inductive and deductive analyses.Results: We identified five main themes pertaining to treatment-related decision-making experiences and fertility issues and fear of progression and recurrence: Becoming aware of infertility as a potential consequence of cancer treatment; Balancing-prioritising cancer and fertility; Decisions about treatments; Evaluation of treatment decisions; and The consequences of treatments. Sub-themes have also been reported. Different factors such as whether the cancer is breast or gynaecological, physicians' willingness of discussing fertility, influence of others in decision-making, childbearing and relationship status as well as fear of cancer recurrence emerged as important.Conclusion: The importance of physicians directly addressing fertility preservation in the process of treatment decision-making and not treating it as an “add-on” was evident. Satisfaction with treatment decisions depended on both the quality of the process of decision making and its outcome. Fear of recurrence was present in different parts of the adaptation process from illness perceptions to post-treatment evaluation of decisions. Both Common-Sense Model and shared decision-making model were helpful in understanding and explaining young women's experience of treatment decision-making and fertility concerns.

Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).

5039 Background: Plasma ctDNA is a promising minimally invasive biomarker in mCRPC. Pre-treatment high levels of ctDNA reflect poor prognosis (Romanel et al, Sci Transl Med 2015; Annala et al, Cancer Discov 2018). However, the role of plasma ctDNA in prostate tumour monitoring is largely unexplored. We aimed to determine if monitoring tumour response by quantifying ctDNA levels in plasma could enable early assessment of therapy efficacy for mCRPC. Methods: Between January 2011 and June 2016, 132 sequential plasma samples from 54 mCRPC patients (pts) (30 pre- and 24 post-chemotherapy) treated with abiraterone (abi) were collected. Targeted next-generation sequencing was performed on the PGM Ion Torrent using a 316 or 318 Chip to account for 1000X expected coverage per target. We estimated the global tumour content for each sequential plasma sample from study patients by using the approach developed in (Carreira et al, Sci Trasl Med 2014; Romanel et al, Sci Transl Med 2015 ), which extends the CLONET framework (Prandi et al, Genome Biol 2014). Prostate Cancer Working Group -3 (PCWG3) criteria were used to assess clinical, biochemical (PSA) and radiographic (RAD) progression disease (PD). We considered ctDNA PD any increase of ctDNA from baseline value. Results: In our cohort of 54 pts (median age: 75 years, range 70-78), we observed 17 (31.5%) PD, 14 (25.9%) stable disease, and 23 (42.6%) partial/complete response after the first 3 months (mo) abi therapy. The odds ratio (OR) for PD having any increase in ctDNA and a PSA decline < 50% at ~3-mo therapy was 10.83, 95% CI 2.55-45.95, P = 0.001, and 3.27, 95% CI 0.89-12.3, P = 0.074, respectively. In addition, we assessed all 3 types of median PD time from starting abi treatment, suggesting the ability of ctDNA variation to predict overall PD [RAD PD = 6.8 mo, PSA PD = 4.4 mo, and ctDNA PD = 3.0 mo, P = 0.008). An increase of ctDNA levels during the first 3-mo abi treatment was significantly associated with a long-term androgen deprivation therapy (ADT) before plasma sample collection (previous ADT > 24 mo vs 12 > previous ADT ≤23 mo vs < 12 mo: P = 0.036). Conclusions: In mCRPC, an early change in ctDNA fraction may be considered as a predictive biomarker playing a key role in individualized disease monitoring. Prospective evaluation of treatment decisions based on ctDNA is now required.

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

BackgroundThere is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.MethodsWe optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial).ResultsIn the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74–9.10; P < 0.001 and HR 3.81; 95% CI 2.28–6.37; P < 0.001, respectively], PFS (HR 2.18; 95% CI 1.08–4.39; P = 0.03, and HR 1.95; 95% CI 1.23–3.11; P = 0.01, respectively) and rate of PSA decline ≥50% [odds ratio (OR), 4.7; 95% CI 1.17–19.17; P = 0.035 and OR, 5.0; 95% CI 1.70–14.91; P = 0.003, respectively]. AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47–not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94–9.68; P < 0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26–19.93; P < 0.001) and OS (HR 11.08; 95% CI 2.16–56.95; P = 0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts.ConclusionPlasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required.Clinical Trial numberNCT02288936 (PREMIERE trial).

Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).

5060 Background: There is an urgent need to identify biomarkers to guide personalized therapy in CRPC. We aimed to clinically qualify the association of AR status in plasma DNA with worse outcome in pre- and post-docetaxel (doc) CRPC. Methods: We used droplet digital (dd)PCR to assess AR copy number (CN) and mutations (mut) (2105T &gt; A (p.L702H) and 2632A &gt; G (p.T878A) status in plasma DNA from 171 patients (pts) treated with abi/enza in biomarker protocols at 2 institutions. The aim to evaluate plasma AR was defined after sample collection but prior to analysis. Results: We first optimised multiplex ddPCR to accurately define AR status and identified an AR CN cutpoint = 2.01 as having the greatest likelihood to split pts into 2 prognostic groups. We confirmed a strong agreement between ddPCR and NGS for quantitating AR CN and mut allelic frequency (Bland-Altman test: mean difference -0.02 95%CI -2.45 to 2.41; mean difference -0.01 95%CI -0.015 to 0.016 respectively). AR CN gain was observed in 10 (14%) pre- and 33 (34%) postdoc pts and associated with a worse OS (HR 3.98 95%CI 1.74-9.10 p &lt; 0.001; HR 3.81 95%CI 2.28-6.37 p &lt; 0.001 respectively), PFS (HR 2.18 95%CI 1.08-4.39 p = 0.03; HR 1.95 95%CI 1.23-3.11 p = 0.01 respectively) and PSA decline ≥50% (OR 4.7 95%CI 1.17-19.17 p = 0.035; OR 5.0 95%CI 1.70-14.91 p = 0.003 respectively). AR mut were observed in 8 (11%) postdoc but no pre-doc abi-treated pts and also associated with worse OS (HR 3.26 95%CI 1.47-not reached p = 0.004). There was no interaction between AR and doc status (p = 0.83 for OS, p = 0.99 for PFS). Multivariate analysis, adjusting for AR CN and mut, previous doc, double stranded DNA concentration, LDH, confirmed AR status was independently associated with OS (HR 3.77 95%CI 2.42-5.88 p &lt; 0.001 and HR 2.76 95%CI 1.26-6.07 p = 0.011 for AR CN and mut respectively) and PFS (HR 1.96 95% CI 1.32-2.93 p = 0.001). Conclusions: Plasma AR status assessment using multiplex ddPCR identifies CRPC with worse outcome to enza/abi in pre/postdoc CRPC. Additional clinical qualification is available from the PREMIERE study (Grande et al;ASCO2017;Abstract#). Prospective evaluation of treatment decisions based on plasma AR is now required.

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospective evaluation of treatment decisions, a questionnaire was sent to the clinical partner. Regarding the molecular EP class, samples from 56 patients (33.5%) had a low-risk, whereas 111 patients (66.5%) showed a high-risk gene profile. After integration of the clinicopathological factors the combined clinical and molecular score (EPclin) resulted in a low-risk group of 77 patients (46.4%), while 89 (53.6%) had a high risk EPclin score. The EPclin-based estimated median 10-year-risk for metastases with endocrine therapy alone was 11% for the whole cohort. The median handling time averaged three days (range: 0 to 11 days), 59.3% of the tests could be performed in three or less than three days. Comparison of pre- and post-test therapy decisions showed a change of therapy in 37.7% of patients. 16 patients (12.3%) had a change to an additional chemotherapy while 25.4% of patients (n = 33) changed to an endocrine therapy alone. In 73 patients (56.2%) no change of therapy resulted. In 6.1% of patients (n = 8), the patients did not agree to the recommendation of the tumor board. Our results show that the EndoPredict assay could be routinely performed in decentral molecular pathology laboratories and the results markedly change treatment decisions.

Relationships Between Life Attitude Profile and Symptoms Experienced With Treatment Decision Evaluation in Patients With Cancer

Despite many researches that have examined life attitude profile, treatment decision evaluation, and symptoms experienced in cancer populations, the relationships between life attitude profile and symptoms experienced with treatment decision evaluation are still not well understood. A thorough understanding of these relationships is critical for health care professionals to provide appropriate management to patients. The aim of this study was to determine relationships among life attitude profile, the treatment decision evaluation, and symptoms experienced in Turkish patients with cancer. A convenience sample of 199 patients with cancer at a Turkish university hospital completed a structured questionnaire including demographic characteristics and the Life Attitude Profile-Revised Scale for patients with cancer in 2007. The researchers visited the oncology clinic 5 work days every week and conducted interviews with the patients. The life attitude profile was not correlated with the treatment decision evaluation and symptoms experienced (r = 0.082, r = -026). The treatment decision evaluation showed that the patients were uncertain about their satisfaction with the treatment decision. Significant correlations were found between the treatment decision evaluation and symptoms experienced (r = 0.206; P <.01). Holistic nursing interventions can be implemented as they promote healing of the whole person processes as facilitating self-awareness, living meaningfully, and promotion connection with others and with nature and a higher power.

Global Connections: Telemedicine as a Tool to extend Trauma Education

ABSTRACT Introduction Telemedicine is revolutionizing the delivery of trauma care and education. The International Trauma Tele- Grand Rounds is a series that unites institutions worldwide to discuss complex clinical cases and advanced trauma and critical care topics. Materials and methods Multiple remote institutions connect simultaneously to discuss the management of a trauma patient from the prehospital phase to discharge. Weekly, a case is presented in English by one institution on a rotating basis. Key points include mechanism of injury, resuscitation, laboratory and imaging diagnostics, surgical interventions, postoperative patient care, evaluation of treatment decisions and review of the literature. The highly interactive format allows participants to evaluate differences in trauma care across international health systems. Results During 2010 to 2011, 68 sessions were documented. Cases include blunt (42.6%), penetrating (48.5%), blast (7.4%) and crushing (1.5%) traumas. Gunshot wounds were the most frequent (25%). A holistic range of injuries were represented including injuries to major arteries, veins, lungs, heart, pericardium, esophagus, diaphragm, abdominal wall, stomach, intestines, liver, kidneys, pelvis, and the extremities. A variety of surgical and nonsurgical interventions were explored. To date, there have been 42 participating institutions from the United States, Brazil, Colombia, Bahamas, Canada, Mexico, Venezuela, Argentina, Panama, Puerto Rico, Dominican Republic, British Virgin Islands, Spain, Thailand, Turkey and Iraq; ranging from academic medical centers military hospitals, community hospitals, and rural hospitals. In 2011, the series received accreditation by the Accreditation Council for Continuing Medical Education. Conclusion Telemedicine offers a solution to address the disparities in access to trauma care and education. The diversity of institutional settings allows participants to learn from others on how to best treat trauma patients, despite differences in resources and expertise. In addition to serving as an educational tool, the series provides a mechanism for physicians to network and collaborate on future endeavors. How to cite this article Marttos AC, Kuchkarian FM, Rojas DF, Fraga GP, Collet-Silva FS, de Almeida Costa C, Garcia GD, Ginzburg E, Schulman CI, Namias N. Global Connections: Telemedicine as a Tool to extend Trauma Education. Panam J Trauma Critical Care Emerg Surg 2013;2(1):62-66.

Predictors of treatment decision evaluation in patients with cancer

The purpose of this study was to examine the predictors of treatment decision evaluation in patients with cancer. A convenience sample of 199 patients with cancer at a Turkish university hospital completed a structured questionnaire including demographic characteristics and the treatment decision evaluation for patients with cancer in 2006. In analysis of the data, descriptive statistics, and multiple regression analysis were used. The mean scores of the treatment decision evaluation's subscales showed that the patient were uncertain about their satisfaction with the treatment decision. The mean score of the symptom inventory suggested that the patients had moderate-level symptoms. Education level, marital status, and the severity symptoms of the independent variables were effective predictors of the treatment decision evaluation. Together the independent variables explained 18.7% of the variance of the satisfaction-uncertainty dimension, 9.1% of the variance of the informed choice dimension, and 16% of the variance of the decision control dimension. Overall the independent variables explained 8.3% of the variance of the treatment decision evaluation. The results in this study should increase the awareness of cancer care professionals about a range of treatment decision evaluation and may help them to target particular patient groups for particular support interventions and informed treatment decision.

Psychometric properties of the Treatment Decision Evaluation Scale in patients with cancer in Turkey

This paper is a report of a study to adapt the treatment decision evaluation scale for Turkish patients with cancer and to evaluate its psychometric properties. In 2006 a convenience sample of 199 patients with cancer at a Turkish university hospital completed a structured questionnaire including demographic characteristics and the treatment decision evaluation scale for patients with cancer. Item analysis, principal component analysis, internal consistency reliability, Cronbach's alpha, paired t-test and correlations were used to measure the psychometric properties of the items of the scale. In the assessment of construct validity, there were identified three factors with eigenvalues greater than 1 explained 43.3% of the total variance (Satisfaction–Uncertainty, Informed Choice and Decision Control). Factor analysis yielded that all of factor loadings were above 0.40 and factor loadings of the items ranged from 0.42 to 0.69 in the scales. Internal reliability coefficients of these three factors were found to be good, 0.74, 0.75 and 0.71, respectively. The present study provides evidence of the treatment decision evaluation scale's validity, reliability and acceptability in Turkish cancer patients. This scale should be further evaluated in different regions in Turkey and diverse populations. The scale has potential applications as it can be used both as a research or a regular treatment decision evaluation tool with clinical settings.

An evaluation of treatment decisions at a colorectal cancer multi‐disciplinary team

It is mandatory for treatment decisions for patients with colorectal cancer to be made within the context of a multi-disciplinary team (MDT) meeting. It is currently uncertain, however, how to best evaluate the quality of MDT decision-making. This study examined MDT decision-making by studying whether MDT treatment decisions were implemented and investigated the reasons why some decisions changed after the meeting. Consecutive MDT treatment decisions were prospectively recorded. Implementation of decisions was studied by examining hospital records. Reasons for changes in MDT decisions were identified. In all, 201 consecutive treatment decisions were analysed, concerning 157 patients. Twenty decisions (10.0%, 95% confidence interval 6.3-15.2%) were not implemented. Looking at the reasons for nonimplementation, nine (40%) related to co-morbidity, seven (35%) to patient choice, two changed in light of new clinical information, one doctor changed a decision and for one changed decision, no reason was apparent. When decisions changed, the final treatment was always more conservative than was originally planned and decisions were more likely to change for colon rather than rectal cancer (P = 0.024). The vast majority of colorectal MDT decisions were implemented and when decisions changed, it mostly related to patient factors that had not been taken into account. Analysis of the implementation of team decisions is an informative process to monitor the quality of MDT decision-making.

Reframing hope: meaning-centered care for patients near the end of life. Interview by Karen S. Heller.

979 Dr. William Breitbart, chief of the Psychiatry Service at Memorial Sloan-Kettering Cancer Center in New York City, describes his current research on a meaning-centered psychotherapeutic intervention that he has designed in order to help terminally ill patients with cancer sustain hope and meaning as they approach the end of their lives. Drawing inspiration and ideas from the works of psychiatrist and Holocaust survivor Viktor Frankl, Dr. Breitbart and his fellow, Dr. Mindy Greenstein, designed an 8-week, group-focused, manualized course of experiential exercises, which is being compared to an 8-week, manualized cancer support group intervention, to see how well meaning-focused care can address a constellation of constructs that he and his colleagues are calling “despair at the end of life.” The component constructs of despair at the end of life include hopelessness, depression, loss of meaning, suicidal ideation, and desire for hastened death. In the following interview with Innovations Associate Editor Karen S. Heller, Dr. Breitbart describes the conceptual evolution of his thinking about despair at the end of life, and details the research on meaning-centered psychotherapy in which he is now engaged. Although the study is still ongoing, preliminary findings suggest that although both types of group intervention reduce patients’ psychological distress and depression and enhance social support, the meaning-centered intervention is more effective in increasing spiritual well-being and a sense of meaning, and in reducing hopelessness and desire for death.

Rationality in medical treatment decisions: is there a sunk-cost effect?

Objective: To assess residents' propensity to display the sunk-cost effect, an irrational decision-making bias, in medical treatment decisions; and to compare residents' and undergraduates' susceptibility to the bias in non-medical, everyday behaviors. Design: Cross-sectional, in-person survey. Setting: Louisiana State University, two locations: Medical Center-Baton Rouge and Main Campus-Psychology Department. Participants: Internal medicine and family practice residents ( N=36, Mdn age=27) and college undergraduates ( N=40, Mdn age=20). Measurements and main results: Residents evaluated medical and non-medical situations that varied the amount of previous investment and whether the present decision maker was the same or different from the person who had made the initial investment. They rated reasons both for continuing the initial decision (e.g., stay with the medication already in use) and for switching to a new alternative (e.g., a different medication). There were two main findings: First, the residents' ratings of whether to continue or switch medical treatments were not influenced by the amount of the initial investment ( p's>0.05). Second, residents' reasoning was more normative in medical than in non-medical situations, in which it paralleled that of undergraduates ( p's<0.05). Conclusions: Medical residents' evaluation of treatment decisions reflected good reasoning, in that they were not influenced by the amount of time and/or money that had already been invested in treating a patient. However, the residents did demonstrate a sunk-cost effect in evaluating non-medical situations. Thus, any advantage in decision making that is conferred by medical training appears to be domain specific.